Notice for regdanvimab (Celltrion Healthcare Australia Pty Ltd)
Active ingredients
regdanvimab
Date of review outcome
Lapse date
Type
Provisional approval
Indication
For treatment of mild to moderate coronavirus disease 2019 (COVID-19) in adult patients who are confirmed to be infected with SARS-CoV-2
Therapeutic area
Infectious diseases